{"publication_id":"d8263221-9f0a-41ec-95ec-4711d2e47db6","content_hash":"sha256:2809a0616979e62f911999dda35626d2bc41e0f83c029591d45638bd417cc1c4","nodes":[{"id":"d8263221-9f0a-41ec-95ec-4711d2e47db6","type":"publication","title":"Research Synthesis: Deuterium Depleted Water — full paper"},{"id":"claim_1","type":"claim","text":"The evidence profile contains no sources classified primarily as direct clinical evidence, 10 adjacent clinical sources, and 4 mechanistic or model-system sources, with 51 cross-study disagreements across the evidence base."},{"id":"claim_2","type":"claim","text":"No single positive outcome class dominates the retained corpus; null signals cluster in the contextual adjacent evidence, mortality and survival and immune and inflammation outcome classes, and negative signals cluster in no dominant outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect."},{"id":"claim_3","type":"claim","text":"The conclusion is that deuterium depleted water should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim."},{"id":"claim_4","type":"claim","text":"This manuscript is reported as a Evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-deuterium_depleted_water-v06-DAILY-2026-06-01T07-37-39Z`."},{"id":"claim_5","type":"claim","text":"The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text."},{"id":"claim_6","type":"claim","text":"Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`."},{"id":"claim_7","type":"claim","text":"Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, immune and inflammation, mortality and survival); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates."},{"id":"claim_8","type":"claim","text":"Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified."},{"id":"claim_9","type":"claim","text":"Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim."},{"id":"claim_10","type":"claim","text":"| Contextual Adjacent Evidence | n=10; claims=199 | no extracted directional signal in 7/10 sources | 5 indirect; 3 mechanistic; 2 review | limited corpus depth in this outcome class |"},{"id":"claim_11","type":"claim","text":"This evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate."},{"id":"claim_12","type":"claim","text":"10 included sources were assigned to this outcome class. Directional coding: null=7, unclear=3. Directness coding: indirect=5, mechanistic=3, review=2."},{"id":"claim_13","type":"claim","text":"4 included sources were assigned to this outcome class. Directional coding: null=3, unclear=1. Directness coding: indirect=3, mechanistic=1."},{"id":"claim_14","type":"claim","text":"1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1."},{"id":"claim_15","type":"claim","text":"1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1."},{"id":"claim_16","type":"claim","text":"Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim."},{"id":"claim_17","type":"claim","text":"The curated corpus lacks any randomized controlled trial of deuterium-depleted water (DDW) and is instead composed entirely of observational cohorts and preclinical models. All clinical evidence derives from uncontrolled designs in which DDW was administered alongside conventional cancer therapy (Somlyai 2025, Somlyai 2023, Boros 2021), making it impossible to isolate the independent contribution of deuterium depletion to the reported survival outcomes. Consequently, the headline conclusion that DDW \"multiplies survival probability\" rests on evidence that cannot meet conventional efficacy thresholds for causal inference."},{"id":"claim_18","type":"claim","text":"Several clinically relevant endpoints are represented by only a single source, precluding internal replication within the corpus. The cardiometabolic outcome class—specifically GLUT4 translocation and insulin-sensitivity markers—is supported by one laboratory study (Kondo 2024) and one preclinical investigation (Molnar 2021), but no human trial has confirmed these glucose-uptake findings in vivo. Immune-inflammation endpoints are likewise touched by a single preclinical source (Rasooli 2019) examining sepsis-induced liver injury in rats, with no corroborating clinical data. Translational relevance to humans remains uncertain. When outcomes depend on lone studies, effect estimates cannot be triangulated and the risk of spurious or context-specific findings remains unquantifiable."},{"id":"claim_19","type":"claim","text":"The population base is narrow, restricting external validity. Clinical cohorts enrolled exclusively adult cancer patients—primarily lung, pancreatic, and glioblastoma subtypes (Somlyai 2025, Somlyai 2023, Boros 2021, Gyongyi 2013)—with no evidence in pediatric, pregnant, or elderly non-oncologic populations. Geographic and institutional diversity is also limited; the Hungarian research group behind Somlyai 2025 and Somlyai 2023 accounts for a substantial share of the clinical data, and independent replication outside this network is absent from the corpus. Preclinical animal studies used young-adult rodents (Halenova 2019, Basov 2019), whose metabolic and deuterium-turnover kinetics may not generalize to aged or metabolically compromised humans. The obesity-relevant rat model (Halenova 2019) demonstrated restored body-weight index and serotonin levels after 3 weeks of DDW at 10 ppm, yet no parallel human dietary-intervention trial exists to bridge this finding."},{"id":"claim_20","type":"claim","text":"The corpus contains a pronounced mechanism-to-clinic gap: cell-level and animal-model evidence for DDW's anticancer and metabolic mechanisms is relatively rich, but corresponding clinical-effectiveness data are sparse. Similarly, DDW-induced GLUT4 translocation and a reported three- to four-fold increase in glucose uptake under insulin-resistant conditions (Kondo 2024) have not been validated against hard cardiometabolic endpoints such as HbA1c reduction toward the 7% target recommended by ADA 2024. Long-term safety data, dose–response characterization in humans, and quality-of-life outcomes are entirely absent from the curated references. Until controlled trials bridge these mechanistic observations to patient-centered endpoints, the therapeutic promise of deuterium-depleted water remains plausible but unproven."},{"id":"claim_21","type":"claim","text":"For deuterium depleted water, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct clinical records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus may support deuterium depleted water as a general health or lifestyle intervention where otherwise indicated, but does not justify marketing it as a standalone geroprotective or anti-aging intervention with proven hard-longevity effects. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging."},{"id":"claim_22","type":"claim","text":"This synthesis maps 16 included sources on Deuterium depleted water across 4 outcome classes and 51 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit."},{"id":"claim_23","type":"claim","text":"Across 16 curated reference papers, the evidence base for Deuterium depleted water shows a context-dependent profile. Null findings dominate: contextual other, mortality survival. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Deuterium depleted water anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established."},{"id":"claim_24","type":"claim","text":"The strongest unresolved contrast is the null vs positive between Somlyai 2023 and Somlyai 2025 on mortality and survival (severity 3/5), which defines the boundary condition future studies must test rather than smooth over."},{"id":"claim_25","type":"claim","text":"This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary."},{"id":"claim_26","type":"claim","text":"| P1 | cardiometabolic: direct clinical gap | 0 direct and 1 indirect source; direction profile: null |"},{"id":"claim_27","type":"claim","text":"| P2 | contextual adjacent evidence: direct clinical gap | 0 direct and 10 indirect sources; direction profile: null, unclear |"},{"id":"claim_28","type":"claim","text":"| P3 | mortality and survival: direct clinical gap | 0 direct and 4 indirect sources; direction profile: null, unclear |"},{"id":"claim_29","type":"claim","text":"| P4 | immune and inflammation: direct clinical gap | 0 direct and 1 indirect source; direction profile: null |"},{"id":"claim_30","type":"claim","text":"The next high-yield study for Deuterium depleted water should target the **cardiometabolic** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction."},{"id":"source_1","type":"source","study":"Somlyai 2025","year":2025,"doi":"10.3390/biomedicines13040876","url":"https://doi.org/10.3390/biomedicines13040876","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_2","type":"source","study":"Somlyai 2023","year":2023,"doi":"10.3390/biomedicines11071989","url":"https://doi.org/10.3390/biomedicines11071989","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_3","type":"source","study":"Boros 2021","year":2021,"doi":"10.1177/1073274821999655","url":"https://doi.org/10.1177/1073274821999655","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_4","type":"source","study":"Korchinsky 2024","year":2024,"doi":"10.1007/s11306-024-02173-4","url":"https://doi.org/10.1007/s11306-024-02173-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_5","type":"source","study":"Molnar 2021","year":2021,"doi":"10.1007/s11010-021-04231-0","url":"https://doi.org/10.1007/s11010-021-04231-0","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_6","type":"source","study":"Yaglova 2024","year":2024,"doi":"10.3390/biomedicines12050956","url":"https://doi.org/10.3390/biomedicines12050956","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_7","type":"source","study":"Lu 2024","year":2024,"doi":"10.3390/nu16091397","url":"https://doi.org/10.3390/nu16091397","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_8","type":"source","study":"Kondo 2024","year":2024,"doi":"10.3390/biomedicines12081771","url":"https://doi.org/10.3390/biomedicines12081771","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_9","type":"source","study":"Li 2025","year":2025,"doi":"10.3892/or.2025.8903","url":"https://doi.org/10.3892/or.2025.8903","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_10","type":"source","study":"Halenova 2019","year":2019,"doi":"10.3390/molecules25010023","url":"https://doi.org/10.3390/molecules25010023","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_11","type":"source","study":"Basov 2019","year":2019,"doi":"10.29252/.23.2.129","url":"https://doi.org/10.29252/.23.2.129","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_12","type":"source","study":"Rasooli 2019","year":2019,"doi":"10.1080/13880209.2018.1563622","url":"https://doi.org/10.1080/13880209.2018.1563622","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_13","type":"source","study":"Zhang 2019","year":2019,"doi":"10.1074/mcp.RA119.001455","url":"https://doi.org/10.1074/mcp.RA119.001455","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_14","type":"source","study":"Basov 2019b","year":2019,"doi":"10.3390/nu11081903","url":"https://doi.org/10.3390/nu11081903","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_15","type":"source","study":"Gyongyi 2013","year":2013,"doi":"10.1080/01635581.2013.756533","url":"https://doi.org/10.1080/01635581.2013.756533","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_16","type":"source","study":"Goncharuk 2013","year":2013,"doi":"10.1186/1752-153X-7-103","url":"https://doi.org/10.1186/1752-153X-7-103","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_17","type":"source","study":"ADA 2024","year":null,"doi":"10.2337/dc24-S006","url":"https://doi.org/10.2337/dc24-S006","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"}],"edges":[{"from":"d8263221-9f0a-41ec-95ec-4711d2e47db6","to":"claim_1","type":"contains_claim"},{"from":"d8263221-9f0a-41ec-95ec-4711d2e47db6","to":"claim_2","type":"contains_claim"},{"from":"d8263221-9f0a-41ec-95ec-4711d2e47db6","to":"claim_3","type":"contains_claim"},{"from":"d8263221-9f0a-41ec-95ec-4711d2e47db6","to":"claim_4","type":"contains_claim"},{"from":"d8263221-9f0a-41ec-95ec-4711d2e47db6","to":"claim_5","type":"contains_claim"},{"from":"d8263221-9f0a-41ec-95ec-4711d2e47db6","to":"claim_6","type":"contains_claim"},{"from":"d8263221-9f0a-41ec-95ec-4711d2e47db6","to":"claim_7","type":"contains_claim"},{"from":"d8263221-9f0a-41ec-95ec-4711d2e47db6","to":"claim_8","type":"contains_claim"},{"from":"d8263221-9f0a-41ec-95ec-4711d2e47db6","to":"claim_9","type":"contains_claim"},{"from":"d8263221-9f0a-41ec-95ec-4711d2e47db6","to":"claim_10","type":"contains_claim"},{"from":"d8263221-9f0a-41ec-95ec-4711d2e47db6","to":"claim_11","type":"contains_claim"},{"from":"d8263221-9f0a-41ec-95ec-4711d2e47db6","to":"claim_12","type":"contains_claim"},{"from":"d8263221-9f0a-41ec-95ec-4711d2e47db6","to":"claim_13","type":"contains_claim"},{"from":"d8263221-9f0a-41ec-95ec-4711d2e47db6","to":"claim_14","type":"contains_claim"},{"from":"d8263221-9f0a-41ec-95ec-4711d2e47db6","to":"claim_15","type":"contains_claim"},{"from":"d8263221-9f0a-41ec-95ec-4711d2e47db6","to":"claim_16","type":"contains_claim"},{"from":"d8263221-9f0a-41ec-95ec-4711d2e47db6","to":"claim_17","type":"contains_claim"},{"from":"d8263221-9f0a-41ec-95ec-4711d2e47db6","to":"claim_18","type":"contains_claim"},{"from":"d8263221-9f0a-41ec-95ec-4711d2e47db6","to":"claim_19","type":"contains_claim"},{"from":"d8263221-9f0a-41ec-95ec-4711d2e47db6","to":"claim_20","type":"contains_claim"},{"from":"d8263221-9f0a-41ec-95ec-4711d2e47db6","to":"claim_21","type":"contains_claim"},{"from":"d8263221-9f0a-41ec-95ec-4711d2e47db6","to":"claim_22","type":"contains_claim"},{"from":"d8263221-9f0a-41ec-95ec-4711d2e47db6","to":"claim_23","type":"contains_claim"},{"from":"d8263221-9f0a-41ec-95ec-4711d2e47db6","to":"claim_24","type":"contains_claim"},{"from":"d8263221-9f0a-41ec-95ec-4711d2e47db6","to":"claim_25","type":"contains_claim"},{"from":"d8263221-9f0a-41ec-95ec-4711d2e47db6","to":"claim_26","type":"contains_claim"},{"from":"d8263221-9f0a-41ec-95ec-4711d2e47db6","to":"claim_27","type":"contains_claim"},{"from":"d8263221-9f0a-41ec-95ec-4711d2e47db6","to":"claim_28","type":"contains_claim"},{"from":"d8263221-9f0a-41ec-95ec-4711d2e47db6","to":"claim_29","type":"contains_claim"},{"from":"d8263221-9f0a-41ec-95ec-4711d2e47db6","to":"claim_30","type":"contains_claim"}],"screening":{"identified":16,"screened":16,"excluded":0,"included":16,"included_or_retained":16,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"16 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}